{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457130171
| IUPAC_name = (2''S'')-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl-''N''-(4-nitro-3-trifluoromethyl-phenyl)-propionamide
| image = Andarine.svg
| width = 250
<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Investigational New Drug
| legal_status = 
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| IUPHAR_ligand = 7849
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 401900-40-1
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 125236
| PubChem = 9824562
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB07423
| chemical_formula =
| C=19 | H=18
| F=3 | N=3
| O=6
| molecular_weight = 441.357 g/mol
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8000309
| smiles = FC(F)(F)c1cc(ccc1[N+]([O-])=O)NC(=O)[C@@](O)(COc2ccc(cc2)NC(=O)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YVXVTLGIDOACBJ-SFHVURJKSA-N
| synonyms = Acetamidoxolutamide; Androxolutamide; GTx-007; S-4
}}

'''Andarine''' ('''GTx-007''', '''S-4''') is an investigational [[selective androgen receptor modulator]] (SARM) developed by [[Gtx inc|GTX, Inc]] for treatment of conditions such as [[muscle]] wasting, [[osteoporosis]] and [[benign prostatic hypertrophy]],<ref name="ReferenceA">{{cite journal | vauthors = Hott JL, Borkman RF | title = The non-fluorescence of 4-fluorotryptophan | journal = The Biochemical Journal | volume = 264 | issue = 1 | pages = 297–9 | date = November 1989 | pmid = 2604714 | pmc = 1133577 | doi = 10.1124/jpet.102.040840 }}</ref> using the [[nonsteroidal antiandrogen]] [[bicalutamide]] as a lead compound.<ref>{{cite journal | vauthors = Chen J, Kim J, Dalton JT | title = Discovery and therapeutic promise of selective androgen receptor modulators | journal = Molecular Interventions | volume = 5 | issue = 3 | pages = 173–88 | date = June 2005 | pmid = 15994457 | pmc = 2072877 | doi = 10.1124/mi.5.3.7 }}</ref>

Andarine is an orally active [[partial agonist]] for [[androgen receptor]]s. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to [[finasteride]], but without producing any reduction in muscle mass or anti-androgenic side effects.<ref>G{{cite journal | vauthors = Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT | title = Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia | journal = Endocrinology | volume = 145 | issue = 12 | pages = 5420–8 | date = December 2004 | pmid = 15308613 | pmc = 2098692 | doi = 10.1210/en.2004-0627 }}</ref> This suggests that it is able to competitively block binding of [[dihydrotestosterone]] to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the [[Antiandrogen|anti-androgenic]] drugs traditionally used for treatment of BPH.<ref>{{cite journal | vauthors = Gao W, Kim J, Dalton JT | title = Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands | journal = Pharmaceutical Research | volume = 23 | issue = 8 | pages = 1641–58 | date = August 2006 | pmid = 16841196 | pmc = 2072875 | doi = 10.1007/s11095-006-9024-3 }}</ref>

== See also ==
* [[Acetothiolutamide]]
* [[Enobosarm]]

== References ==
{{Reflist|33em}}

{{Androgen receptor modulators}}

[[Category:Hormonal agents]]
[[Category:Carboxamides]]
[[Category:Trifluoromethyl compounds]]
[[Category:Phenol ethers]]
[[Category:Selective androgen receptor modulators]]

{{antineoplastic-drug-stub}}